Aclarion, Inc. (ACONW) Stock Price & Analysis
Aclarion, Inc. (ACONW) rose 6.67% to USD 0.02 as of July 25, 2026 at 21:04 UTC, according to Nexqual real-time market data.
ACONW last closed at USD 0.02; the session ranged USD 0.02–0.02 on volume of 3,535 shares. Market capitalization is —, with a 52-week range of USD 0.02–0.02 (NCM). Source: Nexqual, July 25, 2026 at 21:04 UTC.
Key Statistics (as of July 25, 2026 at 21:04 UTC)
| Price | USD 0.02 |
|---|---|
| Change | ▲ 6.67% (up) |
| Previous Close | USD 0.02 |
| Open | USD 0.05 |
| Day Range | USD 0.02 – 0.02 |
| 52-Week Range | USD 0.02 – 0.02 |
| Volume | 3,535 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (ACONW)
Wall Street analysts rate ACONW "None", per Nexqual as of July 25, 2026 at 21:04 UTC.
| Consensus Rating | None |
|---|
Earnings (ACONW)
| Revenue Estimate | $30,000 |
|---|
Source: Nexqual, July 25, 2026 at 21:04 UTC.
Financials & Fundamentals (ACONW)
| Total Revenue | $77,879 |
|---|---|
| Revenue Growth (YoY) | +11.30% |
| Gross Margin | +19.34% |
| Operating Margin | -14129.33% |
| Profit Margin | +0.00% |
| ROE | -45.43% |
| Current Ratio | 19.65 |
| Total Cash | $19.01M |
| Total Debt | $0 |
| Free Cash Flow | $-4.90M |
Source: Nexqual, July 25, 2026 at 21:04 UTC.
Financial Health Score (ACONW)
Nexqual rates Aclarion, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 21:04 UTC.
| Growth | Strong — Revenue +66% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $19M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -45%, ROA -28.8% |
Ownership (ACONW)
| Float | 2.20M |
|---|
Source: Nexqual, July 25, 2026 at 21:04 UTC.
Leadership (ACONW)
Aclarion, Inc. is led by Brent Ness (age 58), CEO, President & Director, per Nexqual as of July 25, 2026 at 21:04 UTC.
| CEO, President & Director | Brent Ness (age 58) |
|---|---|
| Executive Chairman | Jeffrey John Thramann (age 60) |
| Chief Financial Officer | Gregory A. Gould (age 59) |
| Chief Strategy Officer | Ryan Bond (age 53) |
Major Backers & Investors (ACONW)
Notable institutional backers of Aclarion, Inc. include CAPTRUST Financial Advisors, Palisades Hudson Asset Management, L.P., Clear Street Group Inc., according to Nexqual as of July 25, 2026 at 21:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| CAPTRUST Financial Advisors | 3.92% |
| Palisades Hudson Asset Management, L.P. | 2.8% |
| Clear Street Group Inc. | 2.35% |
Source: Nexqual, July 25, 2026 at 21:04 UTC.
From Aclarion, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Aclarion, Inc. operates as a healthcare technology company in the United States.
- It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments.
- The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.
- It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AIMDW | AINOS INC C/WTS 29/07/2027 (TO | USD 0.12 | ▲ 0% |
| ACON | Aclarion, Inc. | USD 2.42 | ▼ 5.1% |
| ADSEW | ADS-TEC ENERGY PLC Warrant | USD 0.54 | ▲ 3.13% |
| ALVOW | Alvotech Warrant | USD 0.15 | ▲ 0% |
| ANGHW | Anghami Inc. Warrants | USD 0.01 | ▼ 35.79% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 21:04 UTC. This page is informational and not investment advice.